Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1223249 | 0.83 | OPRM1 (0.44) | OPRM1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3750678 | 0.82 | ALDH1A1 (0.44) | SIGMAR1HTTCYP3A4ALDH1A1 | |
| SCHEMBL8106137 | 0.80 | OPRM1 (0.46) | OPRM1SIGMAR1HTTTDP1MAPT | |
| Hydrochloric Acid SCHEMBL8316273 | 0.79 | OPRM1 (0.45) | OPRM1SIGMAR1HTTTDP1MAPT | |
| SCHEMBL9391014 | 0.78 | OPRM1 (0.44) | OPRM1SIGMAR1HTTTDP1ALDH1A1 | |
| SCHEMBL3742443 | 0.78 | KMT2A (0.43) | HTTALDH1A1L3MBTL1 | |
| SCHEMBL3752153 | 0.77 | POLB (0.50) | HTTALDH1A1MAPT | |
| SCHEMBL12084784 | 0.77 | OPRM1 (0.43) | OPRM1SLC6A4HTTTDP1 | |
| SCHEMBL652661 | 0.77 | OPRM1 (0.43) | OPRM1SLC6A4HTTTDP1 | |
| SCHEMBL3746848 | 0.76 | OPRM1 (0.43) | OPRM1SIGMAR1HTTTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298368-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298368-A1 | ANTAGONISTS OF PGD2 RECEPTORS | PTGDR2, PTGDR, LTB4R2 | OPRM1 577/4885SLC6A2 4049/4885SLC6A3 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.